Does TILDRAKIZUMAB Cause Product dose omission issue? 53 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 53 reports of Product dose omission issue have been filed in association with TILDRAKIZUMAB (ILUMYA). This represents 6.1% of all adverse event reports for TILDRAKIZUMAB.
53
Reports of Product dose omission issue with TILDRAKIZUMAB
6.1%
of all TILDRAKIZUMAB reports
7
Deaths
12
Hospitalizations
How Dangerous Is Product dose omission issue From TILDRAKIZUMAB?
Of the 53 reports, 7 (13.2%) resulted in death, 12 (22.6%) required hospitalization.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TILDRAKIZUMAB. However, 53 reports have been filed with the FAERS database.
What Other Side Effects Does TILDRAKIZUMAB Cause?
Death (50)
Drug ineffective (50)
Psoriasis (37)
Urinary tract infection (36)
Pneumonia (33)
Off label use (27)
Condition aggravated (25)
Covid-19 (25)
Inappropriate schedule of product administration (22)
Cerebrovascular accident (20)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which TILDRAKIZUMAB Alternatives Have Lower Product dose omission issue Risk?
TILDRAKIZUMAB vs TILDRAKIZUMAB-ASMN
TILDRAKIZUMAB vs TILIDINE
TILDRAKIZUMAB vs TIMOLOL
TILDRAKIZUMAB vs TIMOLOL\TRAVOPROST
TILDRAKIZUMAB vs TINIDAZOLE